| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial
Exciting news for the readers of Transfusion Science: things are progressing well towards having Transfusion Science serve as the official journal for the World Apheresis Association. This will greatl...
|
G Rock
|
167
|
|
|
|
Single automated donor plateletpheresis increases the plasma level of proinflammatory cytokine tumor necrosis factor-α which does not associate with endothelial release markers von Willebrand factor and fibronectin
Abstract: The effect of plateletpheresis on endothelium, which has strong effects on blood coagulation, fibrinolysis and platelet function, is not known. Activation of leukocytes and subsequent genera...
|
İhsan Karadoğan,
Mustafa Özdoğan,
Levent Ündar
|
171-175
|
|
|
|
Preoperative autologous blood donation in hip surgeries
Abstract: We evaluated the effectiveness of preoperative autologous blood donation in reduction of the need for transfusion of homologous blood in hip surgeries at our hospital. The cases of 55 patien...
|
Teruhiko Azuma,
Shuji Takahashi,
Akio Kawamura
|
177-181
|
|
|
|
Primary and secondary haemochromatosis
Iron-related diseases are a major problem all over the world. In transfusion medicine physicians may relieve discomfort caused by acute or chronic iron deficiency anaemia by giving red cell transfusio...
|
J.J.M Marx
|
183-184
|
|
|
|
The importance of non-transferrin bound iron in disorders of iron metabolism
Abstract: The concept of non-transferrin bound iron (NTBI) was introduced 22 years ago by Hershko et al. (Brit. J. Haematol. 40 (1978) 255). It stemmed from a suspicion that, in iron overloaded patien...
|
W Breuer,
C Hershko,
Z.I Cabantchik
|
185-192
|
|
|
|
Clinical aspects of hemochromatosis
Abstract: Hemochromatosis is one of the most frequent genetic diseases among the white populations, affecting one in three hundred persons. Its diagnosis has been radically transformed by the discover...
|
Pierre Brissot,
Dominique Guyader,
Olivier Loréal,
Fabrice Lainé,
Anne Guillygomarc'h,
Romain Moirand,
Yves Deugnier
et al.
|
193-200
|
|
|
|
The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe3+ values
Transfusion-dependent patients such as those suffering from β-thalassaemia develop a fatal secondary haemosiderosis and consequently, a selective iron chelator must be used to relieve such iron overlo...
|
Robert C. Hider,
Zu D. Liu,
S. Piyamongkol
|
201-209
|
|
|
|
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1)
Abstract: Iron is essential for all living organisms. Under normal conditions there is no regulatory and rapid iron excretion in humans and body iron levels are mainly regulated from the absorption of...
|
George J Kontoghiorghes,
Katerina Pattichi,
Michael Hadjigavriel,
Annita Kolnagou
|
211-223
|
|
|
|
Regulation of intracellular iron levels in iron-acceptor and iron-donor cells
Abstract: In recent years many new genes and proteins were identified with crucial functions in iron metabolism. This gave an explosion of our knowledge and understanding of iron related disorders. Mu...
|
Manuela Santos,
Maria de Sousa,
J.J.M. Marx
|
225-235
|
|
|
|
Free radical formation and oxyhemoglobin oxidation in β-thalassemic red blood cells in the presence of prooxidants: effects of the free radical scavenger rutin and oral chelator L1
It is widely assumed that red blood cells (RBC) from patients with thalassemia (Th-RBC) are subjected to oxidative stress due to abnormal iron deposits on the membrane cytoplasmic surface originated f...
|
Igor B Afanas'ev,
Ilya I Afanas'ev,
Irina B Deeva,
Ludmila G Korkina
|
237-238
|
|
|
|
The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)
The oral iron chelator deferiprone (L1) has now been in use in humans with iron overload for a number of years . Olivieri and Brittenham have presented data indicating a concern that the drug in long...
|
Vasili Berdoukas,
Tim Bohane,
Craig Eagle,
Rob Lindeman,
Keshani DeSilva,
Vivienne Tobias,
Dorothy Painter,
Ian Fraser
et al.
|
239-240
|
|
|
|
Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy
Non-transferrin-bound iron (NTBI) represents various forms of labile iron appearing in the plasma of patients with various pathological conditions. NTBI is most commonly found in patients whose transf...
|
William Breuer,
Marieke J.J Ermers,
Pensri Pootrakul,
Ayala Abramov,
Chaim Hershko,
Z Ioav Cabantchik
et al.
|
241-242
|
|
|
|
The effect of deoxynucleosides on cell proliferation of peripheral blood lymphocytes treated with deferoxamine or hydroxyurea
Deferoxamine (DFO) has anti-retroviral properties for which two mechanisms have been proposed. First, DFO inhibits NF-κB activation by preventing the formation of hydroxyl radicals in the iron-catalyz...
|
Tjomme van der Bruggen,
Niki A Georgiou,
Maroeska Oudshoorn,
Hans S.L.M Nottet,
Joannes J.M Marx,
B.Sweder van Asbeck
et al.
|
243-244
|
|
|
|
Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in β-thalassemia intermedia
Non-transferrin-bound iron (NTBI) is a low molecular weight (LMW) form of iron supposed to arise from iron challenge and to exert direct pro-oxidant catalysis in lipid peroxidation associated to disor...
|
Maria Domenica Cappellini,
Dario Tavazzi,
Lorena Duca,
Susan Marelli,
Gemino Fiorelli
et al.
|
245-246
|
|
|
|
Multiple effects of iron chelators on molecules controlling cell cycle progression
Considering the potential utility of iron (Fe) chelators as anti-neoplastic agents we have examined a wide variety of analogues of pyridoxal isonicotinoyl hydrazone (PIH) as effective anti-proliferati...
|
J Gao,
D.R Richardson
|
247-248
|
|
|
|
Combining iron chelators with the nucleoside analog didanosine in anti-HIV therapy
Iron chelation which would make iron unavailable for redox reactions could influence HIV replication in two possible ways: first, by inactivation of the iron-dependent cellular enzyme ribonucleotide r...
|
Niki A Georgiou,
Tjomme van der Bruggen,
Maroeska Oudshoorn,
Hans H.L.M Nottet,
Joannes J.M Marx,
B Sweder van Asbeck
et al.
|
249-250
|
|
|
|
Endocrine problems in ex-thalassemic patients
Many of the transfused thalassemic patients present endocrine dysfunction and growth disturbances . Bone marrow transplantation (BMT) is the only curative treatment for thalassemia major. We studied t...
|
Antonios C Kattamis,
Marios Antoniadis,
Irene Manoli,
Vasiliki Kitra,
Dimitris Petropoulos,
Stelios Grafakos
et al.
|
251-252
|
|
|
|
L1 effects on reactive oxygen (ROS) and nitrogen species (RNS) release, hemoglobin oxidation, low molecular weight antioxidants, and antioxidant enzyme activities in red and white blood cells of thalassemic patients
It has been demonstrated in a number of papers that patients suffering from β-thalassemia are subjected to in vivo oxidative stress due to the excessive production of reactive oxygen (ROS) by the rea...
|
L Korkina,
C De Luca,
I Deeva,
S Perrotta,
B Nobili,
S Passi,
P Puddu
et al.
|
253-254
|
|
|
|
Morbidity and mortality of iron intoxication in adult patients with thalassemia major, and effectiveness of chelation
Thalassemic patients under conventional treatment, with frequent transfusions and intensive chelation with Desferrioxamine, achieve a substantial increase in survival, supplemented by a considerable i...
|
V Ladis,
H Berdousi,
F Palamidou,
C Agrafioti,
A Papadopoulou,
G Anagnostopoulos,
C Theodorides,
C Kattamis
et al.
|
255-256
|
|
|
|
Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases
In iron overload diseases in humans, the liver is the main place of iron storage accounting for at least 70–90% of the excessive iron burden. SQUID biomagnetic liver susceptometry (BLS) has become a r...
|
P Nielsen,
R Engelhardt,
M Duerken,
G.E Janka,
R Fischer
et al.
|
257-258
|
|
|
|
Competition studies of L1-deferiprone with copper and iron. Possible implications on efficacy, toxicity and new therapeutic applications
1,2-Dimethyl-3-hydroxypyrid-4-one (L1, INN: deferiprone) is a new, orally active chelating drug used worldwide for the treatment of transfusional iron overloading conditions. It shows comparable in vi...
|
I Pashalidis,
G.J Kontoghiorghes
|
259-261
|
|
|
|
Haematopoietic stem cell transplantation for the management of haemoglobinopathies in Greek patients
β-thalassaemia major is a common genetic disease in Greece. Although successful prenatal diagnosis has markedly reduced the incidence of the disease, 5–10 thalassaemic children are still born each yea...
|
J Peristeri,
V Kitra,
E Goussetis,
D Petropoulos,
M Theodosaki,
A Kattamis,
S Graphakos
et al.
|
263-264
|
|
|
|
Hydroxamate analog libraries and evaluation of their iron affinity
The shortcomings of current chelation therapy in iron-overload diseases require the development of novel iron chelators that would be superior to desferrioxamine B (DFO) and more patient-friendly . In...
|
Urszula Slomczynska,
P Amruta Reddy,
Otto Schall,
Leonard Rosik,
James R Wheatley,
Garland R Marshall
et al.
|
265-266
|
|
|
|
A relationship between glucose metabolism and NO-mediated iron mobilization from cells
Nitrogen monoxide (NO) has been shown to have a pronounced effect on intracellular iron (Fe) metabolism due to its high affinity for this metal ion. For example, NO can increase RNA-binding activity o...
|
R.N Watts,
D.R Richardson
|
267-268
|
|
|
|
The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe3+ values
Transfusion dependent patients such as those suffering from β-thalassaemia develop a fatal secondary haemosiderosis and consequently, a selective iron chelator must be used to relieve such iron overlo...
|
Zu D Liu,
S Piyamongkol,
Robert C Hider
|
269-270
|
|
|
|
Post-transfusion thrombocytopenia in recipients with anti-HLA antibody
Abstract: Allogeneic red cell transfusion produced a significant decrease in the platelet counts of recipients who possessed anti-HLA antibodies.
|
Hitoshi Ohto,
Hiroyasu Yasuda,
Hiroo Maeda,
Shoichi Inaba
|
271-273
|
|
|
|
Patent report
|
|
II-VIII
|
|
|
|
Index
|
|
XXI
|
|
|
|
Index
|
|
XXII
|
|
|
|
Index
|
|
XXXII
|
|
|
|
Index
|
|
XXXIII-XXXIV
|
|
